Genesis Research and Development, a New Zealand-based RNAi drug developer, released last week its financial results for 2005, and said that it is on track for initiating a phase I clinical trial as early as the first quarter of next year.
For 2005, Genesis said total revenues fell to NZ$2.6 million ($1.7 million) from $2.9 million, reflecting the completion of certain research collaborations and a reduction in interest income as a result of lower cash funds.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
